Skip to main content
Top
Published in: Advances in Therapy 2/2014

01-02-2014 | Erratum

Erratum to: OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Overactivity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology

Authors: David Ginsberg, Francisco Cruz, Sender Herschorn, Angelo Gousse, Véronique Keppenne, Philip Aliotta, Karl-Dietrich Sievert, Mitchell F. Brin, Brenda Jenkins, Catherine Thompson, Wayne Lam, John Heesakkers, Cornelia Haag-Molkenteller

Published in: Advances in Therapy | Issue 2/2014

Login to get access

Excerpt

The authors would like to make the following correction to the above mentioned article. The title should be changed from “OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Activity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology” to “OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Overactivity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology”. …
Metadata
Title
Erratum to: OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Overactivity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology
Authors
David Ginsberg
Francisco Cruz
Sender Herschorn
Angelo Gousse
Véronique Keppenne
Philip Aliotta
Karl-Dietrich Sievert
Mitchell F. Brin
Brenda Jenkins
Catherine Thompson
Wayne Lam
John Heesakkers
Cornelia Haag-Molkenteller
Publication date
01-02-2014
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 2/2014
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-014-0103-2

Other articles of this Issue 2/2014

Advances in Therapy 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine